![]()
Takanashi, M., H. Mochizuki, et al. (2001). "Iron accumulation
in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP)."
7(4): 311-314.
Autosomal recessive juvenile parkinsonism (ARJP) is a distinct clinical and
genetic entity characterized by highly selective neuronal death in the
substantia nigra (SN) and locus coeruleus neurons without Lewy body formation.
The mechanism of neuronal death of ARJP is still unknown. Our study demonstrated
that iron staining was more intense in ARJP than in both controls and sporadic
Parkinson's disease (PD), and there were differences in the pattern of
distribution of iron staining between ARJP and PD. In addition neurites of SN in
ARJP showed intense iron staining. Thus, we postulate that oxidative stress may
play an important role in the neurodegeneration that occurs in ARJP.
Tan, E. K., S. Nagamitsu, et al. (2001). "Alcohol dehydrogenase polymorphism and
Parkinson's disease." Neurosci Lett 305(1): 70-2.
A particular alcohol dehydrogenase (ADH) polymorphism (allele A1) in the
promoter region of the gene has been recently demonstrated to be associated with
increased risk of Parkinson's disease (PD). In a case control study, we examine
frequencies of ADH A1 allele in 100 PD patients (i.e. 200 alleles), 100 diseased
controls (i.e. 200 alleles), and 194 healthy controls (i.e. 388 alleles). In
addition, we study possible association of a combined non-amyloid component of
plaque (NACP-Rep 1) allele and ADH A1 allele with risk of PD. There was no
statistical significance of the frequencies of ADH A1 allele between PD patients
12/200 (6%), diseased controls 13/200 (6.5%), and healthy controls 20/388
(5.2%). No strong evidence of an association was found between ADH A1 allele and
PD susceptibility in our study patients. There was also no suggestion of linkage
disequilibrium between NACP-Rep 1 and ADH A1 alleles.
Tan, S., N. Somia, et al. (2001). "Regulation of antioxidant metabolism by
translation initiation factor 2alpha." J Cell Biol 152(5):
997-1006.
Oxidative stress and highly specific decreases in glutathione (GSH) are
associated with nerve cell death in Parkinson's disease. Using an experimental
nerve cell model for oxidative stress and an expression cloning strategy, a gene
involved in oxidative stress-induced programmed cell death was identified which
both mediates the cell death program and regulates GSH levels. Two
stress-resistant clones were isolated which contain antisense gene fragments of
the translation initiation factor (eIF)2alpha and express a low amount of
eIF2alpha. Sensitivity is restored when the clones are transfected with
full-length eIF2alpha; transfection of wild-type cells with the truncated
eIF2alpha gene confers resistance. The phosphorylation of eIF2alpha also results
in resistance to oxidative stress. In wild-type cells, oxidative stress results
in rapid GSH depletion, a large increase in peroxide levels, and an influx of
Ca(2+). In contrast, the resistant clones maintain high GSH levels and show no
elevation in peroxides or Ca(2+) when stressed, and the GSH synthetic enzyme
gamma-glutamyl cysteine synthetase (gammaGCS) is elevated. The change in
gammaGCS is regulated by a translational mechanism. Therefore, eIF2alpha is a
critical regulatory factor in the response of nerve cells to oxidative stress
and in the control of the major intracellular antioxidant, GSH, and may play a
central role in the many neurodegenerative diseases associated with oxidative
stress.
Tanaka, Y., S. Engelender, et al. (2001). "Inducible expression of mutant alpha-synuclein
decreases proteasome activity and increases sensitivity to
mitochondria-dependent apoptosis." Hum Mol Genet 10(9): 919-26.
Parkinson's disease (PD) is a common progressive neurodegenerative disorder
caused by the loss of dopaminergic neurons in the substantia nigra. Although
mutations in alpha-synuclein have been identified in autosomal dominant PD, the
mechanism by which dopaminergic neural cell death occurs remains unknown.
Proteins encoded by two other genes in which mutations cause familial PD, parkin
and UCH-L1, are involved in regulation of the ubiquitin-proteasome pathway,
suggesting that dysregulation of the ubiquitin-proteasome pathway is involved in
the mechanism by which these mutations cause PD. We established inducible PC12
cell lines in which wild-type or mutant alpha-synuclein can be de-repressed by
removing doxycycline. Differentiated PC12 cell lines expressing mutant alpha-synuclein
showed decreased activity of proteasomes without direct toxicity. Cells
expressing mutant alpha-synuclein showed increased sensitivity to apoptotic cell
death when treated with sub-toxic concentrations of an exogenous proteasome
inhibitor. Apoptosis was accompanied by mitochondrial depolarization and
elevation of caspase-3 and -9, and was blocked by cyclosporin A. These data
suggest that expression of mutant alpha-synuclein results in sensitivity to
impairment of proteasome activity, leading to mitochondrial abnormalities and
neuronal cell death.
Tang, K., M. J. Low, et al. (2001). "Dopamine-dependent synaptic plasticity in
striatum during in vivo development." Proc Natl Acad Sci U S A 98(3):
1255-60.
The neurotransmitters dopamine (DA) and glutamate in the striatum play key roles
in movement and cognition, and they are implicated in disorders of the basal
ganglia such as Parkinson's disease. Excitatory synapses in striatum undergo a
form of developmental plasticity characterized by a decrease in glutamate
release probability. Here we demonstrate that this form of synaptic plasticity
is DA and DA D2 receptor dependent. Analysis of spontaneous synaptic responses
indicates that a presynaptic mechanism involving inhibition of neurotransmitter
release underlies the developmental plasticity. We suggest that a major role of
DA in the striatum is to initiate mechanisms that regulate the efficacy of
excitatory striatal synapses, producing a decrease in glutamate release.
Tang, X. D., H. Daggett, et al. (2001). "Oxidative regulation of large
conductance calcium-activated potassium channels." J Gen Physiol 117(3):
253-74.
Reactive oxygen/nitrogen species are readily generated in vivo, playing roles in
many physiological and pathological conditions, such as Alzheimer's disease and
Parkinson's disease, by oxidatively modifying various proteins. Previous studies
indicate that large conductance Ca(2+)-activated K(+) channels (BK(Ca) or Slo)
are subject to redox regulation. However, conflicting results exist whether
oxidation increases or decreases the channel activity. We used chloramine-T,
which preferentially oxidizes methionine, to examine the functional consequences
of methionine oxidation in the cloned human Slo (hSlo) channel expressed in
mammalian cells. In the virtual absence of Ca(2+), the oxidant shifted the
steady-state macroscopic conductance to a more negative direction and slowed
deactivation. The results obtained suggest that oxidation enhances specific
voltage-dependent opening transitions and slows the rate-limiting closing
transition. Enhancement of the hSlo activity was partially reversed by the
enzyme peptide methionine sulfoxide reductase, suggesting that the upregulation
is mediated by methionine oxidation. In contrast, hydrogen peroxide and cysteine-specific
reagents, DTNB, MTSEA, and PCMB, decreased the channel activity. Chloramine-T
was much less effective when concurrently applied with the K(+) channel blocker
TEA, which is consistent with the possibility that the target methionine lies
within the channel pore. Regulation of the Slo channel by methionine oxidation
may represent an important link between cellular electrical excitability and
metabolism.
Tanner, C. M., S. M. Goldman, et al. (2001). "Essential tremor in twins: An
assessment of genetic vs environmental determinants of etiology." Neurology
57(8): 1389-91.
OBJECTIVE: - To determine the relative contribution of genetics and environment
to essential tremor using a twin study method. METHODS: - Twins with postural or
kinetic tremor were identified by movement disorders specialists during the
conduct of a study investigating PD in members of the National Academy of
Sciences and National Research Council World War II Veteran Twins Registry. The
diagnosis of essential tremor was made by consensus using established diagnostic
criteria. RESULTS: - A total of 196 twins had postural or kinetic tremor on
examination. Of these, 137 had PD or had a twin with PD and were excluded from
this study. Thirty-three others were excluded because of incomplete data for
their twin. Sixteen twin pairs were identified in which at least one twin had
essential tremor. Pairwise concordance in monozygotic twins was approximately
two times that in dizygotic twins (0.60 monozygotic, 0.27 dizygotic).
CONCLUSION: - This pattern is consistent with a genetic cause of essential
tremor. Because monozygotic concordance is not 100%, environmental factors may
also play a role in the cause of the disease.
Tayebi, N., M. Callahan, et al. (2001). "Gaucher disease and parkinsonism: a
phenotypic and genotypic characterization." Mol Genet Metab 73(4):
313-21.
Among the many phenotypes associated with Gaucher disease, the inherited
deficiency of glucocerebrosidase, are reports of patients with parkinsonian
symptoms. The basis for this association is unknown, but could be due to
alterations in the gene or gene region. The human glucocerebrosidase gene,
located on chromosome 1q21, has a nearby pseudogene that shares 96% identity.
Immediately adjacent to the glucocerebrosidase pseudogene is a convergently
transcribed gene, metaxin, which has a pseudogene that is located just
downstream to the glucocerebrosidase gene. We describe a patient with mild
Gaucher disease but impaired horizontal saccadic eye movements who developed a
tremor at age 42, followed by rapid deterioration of her gait. A pallidotomy at
age 47 was unsuccessful. Her motor and cognitive deterioration progressed
despite enzyme replacement therapy. Sequencing of the glucocerebrosidase gene
identified mutations L444P and D409H. Southern blot analysis using the enzyme
SspI showed that the maternal allele had an additional 17-kb band. PCR
amplifications and sequencing of this fragment demonstrated a duplication which
included the glucocerebrosidase pseudogene, metaxin gene, and a pseudometaxin/metaxin
fusion. Gene alterations associated with this novel rearrangement, resulting
from a crossover between the gene for metaxin and its pseudogene, could
contribute to the atypical phenotype encountered in this patient.
Taylor, M. C., P. G. Board, et al. (2001). "Zeta class glutathione transferase
polymorphisms and Parkinson's disease." J Neurol Neurosurg Psychiatry
70(3): 407.
Theofilopoulos, S., J. Goggi, et al. (2001). "Parallel induction of the
formation of dopamine and its metabolites with induction of tyrosine hydroxylase
expression in foetal rat and human cerebral cortical cells by brain-derived
neurotrophic factor and glial-cell derived neurotrophic factor." Brain Res
Dev Brain Res 127(2): 111-22.
Brain-derived neurotrophic factor (BDNF; 50 ng/ml), dopamine (DA; 10 microM) and
forskolin (Fsk; 10 microM) have previously been shown by this and other
laboratories to induce the tyrosine hydroxylase (TH) enzyme in foetal human and
rat cerebral cortex during specified sensitive developmental periods. In the
present study, these findings were extended for human and rat cells by showing
that the induced TH+ cells also produce dopamine and its metabolite
3,4-dihydroxyphenylacetic acid (DOPAC). In addition to this, TH induction and DA
plus DOPAC production was observed in foetal human and rat cerebral cortex by
using glial-cell derived neurotrophic factor (GDNF) in place of BDNF. The degree
of induction by GDNF (1-10 ng/ml) was similar to that produced by BDNF and did
not increase further when the two neurotrophic factors were used together. The
time-course of induction in human cultures was followed: GDNF was found to cause
a more rapid induction process than BDNF during the first 2 weeks. However the
degree of induction after 3 weeks was the same for both neurotrophic factors.
Inhibitors of transcription (actinomycin D) or of translation (cycloheximide)
eliminated all the increase in DA+DOPAC contents elicited by these compounds,
indicating that de novo transcription and translation were required for
increased expression of the TH and other related enzymes. The intracellular
pathways by which these molecules exert this dopaminergic phenotype induction
effect are discussed. This study indicates a new source of dopaminergic brain
tissue for use as transplants to neurosurgically treat Parkinson's disease
patients.
Tieu, K., P. C. Ashe, et al. (2001). "Inhibition of 6-hydroxydopamine-induced
p53 expression and survival of neuroblastoma cells following interaction with
astrocytes." Neuroscience 103(1): 125-32.
The neurotoxin 6-hydroxydopamine has been used to induce selective dopaminergic
cell death in animal models of Parkinson's disease. The response of neurons to
this toxin has been shown to be greatly influenced by astrocytes. Our laboratory
reported previously that human neuroblastoma SH-SY5Y cells became more resistant
to the toxicity of 6-hydroxydopamine when co-cultured with mouse astrocytes.
This enhanced tolerance required direct and specific adhesion between SH-SY5Y
cells and astrocytes. We hypothesized that this interaction led to biochemical
changes in SH-SY5Y cells, thereby protecting these cells from toxicity. To study
these changes, we again co-cultured SH-SY5Y cells with astrocytes and treated
them with 6-hydroxydopamine. An optimized condition of trypsin treatment was
employed to separate SH-SY5Y cells from astrocytes quickly. Western blot
analysis demonstrated that 6-hydroxydopamine significantly increased p53 protein
in monolayer SH-SY5Y cells grown in either regular medium or conditioned medium
from astrocytes. This change, however, was not observed in the group co-cultured
with astrocytes. Data obtained from the ribonuclease protection assay indicated
that similar changes also occurred at the transcriptional level. The enhanced
resistance of the co-cultured SH-SY5Y cells to the toxicity of 6-hydroxydopamine
is attributed to the ability of astrocytes to prevent the increase of p53
induced by this toxin. This study demonstrates the significance of the
interaction between astrocytes and neurons when they are exposed to neurotoxins.
Tilgner, J., B. Volk, et al. (2001). "Continuous interleukin-6 application in
vivo via macroencapsulation of interleukin-6-expressing COS-7 cells induces
massive gliosis." Glia 35(3): 234-45.
The inflammatory cytokine interleukin-6 (IL-6) was found in senile plaques of
Alzheimer's patients and might be involved in the pathology of Parkinson's
disease and multiple sclerosis. Interestingly, an astocytosis is also found in
these neurodegenerative disorders. To evaluate the direct effects of IL-6 in
vivo on glial cells, we created a new in vivo model. IL-6 and mock-transfected
(control group) COS-7 cells were encapsulated in a poly-acryl-nitril membrane
for implantation into the rat striatum. Afterward, the host immune reaction to
the membrane without encapsulated cells and the biological action of
IL-6-producing capsules was evaluated. Animals with an implanted membrane
without cells showed a moderate astrocytosis 5 days after the operation.
Furthermore, microglia and T-cells could be detected and after 30 days the
astrocytosis decreased to a small layer around the membrane. In comparison to
the control group, which received a sham operation, our results demonstrate that
the response of glial cells is caused by the mechanical damage of the surgical
procedure itself rather than due to the introduced membrane material. In
contrast, we found a massive proliferation and activation of astrocytes and
microglia after 10 days by IL-6-secreting capsules, indicating that IL-6 is
involved in the induction of gliosis. Control animals that received encapsulated
mock-transfected COS-7 cells showed only a weak response. These data point to an
involvement of IL-6 in the proliferation and activation of glial cells as seen
in neurodegenerative disorders.
Tomonaga, K., T. Kobayashi, et al. (2001). "[The neuropathogenesis of Borna
disease virus infection]." Nippon Rinsho 59(8): 1605-13.
Borna disease virus(BDV) is a noncytolytic, neurotropic RNA virus that causes a
disease of the central nervous system(CNS) in several vertebrate species,
including horses, sheep, cats and ostriches. Epidemiological studies using
peripheral blood or brain samples revealed that BDV can infect humans and that
it may be related with certain neuropsychiatric disorders. The unique genetic
and biological properties of BDV indicate that BDV develops a persistent
infection in the CNS. Furthermore, a line of recent evidences suggests that BDV
infection causes direct effects on brain functions in the absence of
immunopathology-related brain damage. In this review, we discuss about recent
data regarding neuropathogenesis of BDV infections in animals and humans.
Touchman, J. W., A. Dehejia, et al. (2001). "Human and mouse alpha-synuclein
genes: comparative genomic sequence analysis and identification of a novel gene
regulatory element." Genome Res 11(1): 78-86.
The human alpha-synuclein gene (SNCA) encodes a presynaptic nerve terminal
protein that was originally identified as a precursor of the non-beta-amyloid
component of Alzheimer's disease plaques. More recently, mutations in SNCA have
been identified in some cases of familial Parkinson's disease, presenting
numerous new areas of investigation for this important disease. Molecular
studies would benefit from detailed information about the long-range sequence
context of SNCA. To that end, we have established the complete genomic sequence
of the chromosomal regions containing the human and mouse alpha-synuclein genes,
with the objective of using the resulting sequence information to identify
conserved regions of biological importance through comparative sequence
analysis. These efforts have yielded approximately 146 and approximately 119 kb
of high-accuracy human and mouse genomic sequence, respectively, revealing the
precise genetic architecture of the alpha-synuclein gene in both species. A
simple repeat element upstream of SNCA/Snca has been identified and shown to be
necessary for normal expression in transient transfection assays using a
luciferase reporter construct. Together, these studies provide valuable data
that should facilitate more detailed analysis of this medically important gene.
Turner, C. and A. H. Schapira (2001). "Mitochondrial dysfunction in
neurodegenerative disorders and ageing." Adv Exp Med Biol 487:
229-51.
![]()